ARVINAS, INC.
Last · —$6.82-0.02 (-0.29%)live · yahoo · 0s ago
Market cap$445.93M—
P/E · TTM26.2fwd — · eps —
Beta—vs S&P 500
Div yield—annual · TTM
52w range
——
Volume—session
| Revenue | $316.7M |
|---|---|
| Operating income | $100.3M |
| Net income | $111.8M |
| Free cash flow | $-119.0M |
| Operating margin | 31.7% |
| Net margin | 35.3% |
| Return on equity | 19.9% |
| Period | TTM 2026-06-30 |
Loading chart…
OpenFilings analyst
Our analyst
From latest 10-K · 2026-02-24
- Operating Cf Burn
- Net Margin Sharply Negative
- Cash Conversion Weak
- Cash Runway Low
- Sbc Revenue Elevated
- Accumulated Deficit High
- Rd Intensity High
Red flags
- Operating Cf Burn — Negative operating cash flow
- Net Margin Sharply Negative — Net margin -30.8%
- Cash Conversion Weak — Cash conversion (CFO/Rev) -104.3%
- Cash Runway Low — Cash runway ~0.5 years
- Sbc Revenue Elevated — SBC/Revenue 16.8%
- Accumulated Deficit High — Accumulated deficit / equity 372%
- Rd Intensity High — R&D/Revenue 108.6%
Upcoming earnings
1:30 PM UTC+1
Period
Sep 2026
Est. EPS
−$0.95
Est. revenue
16.8M
Earnings transcripts
Press & signals
- GlobeNewswire
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- GlobeNewswire
Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate
- GlobeNewswire
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
The rest of this company's wire — with summaries and source links — is part of Pro.
See plans